Tarik Lalwani, MD
Nephrology · Atlanta, GANPI 1376606087
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $43,996 of the $69,037 with a category attached, or 63.7%. 23 manufacturers reported payments, led by AstraZeneca at 41.3% of the total. Reporting peaked in 2019 at $21,307 and has fallen 70.2% since, to $6,341 in 2025. Among nephrology clinicians in GA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 369 payments — averaging $187.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$29K
- Travere Therapeutics, Inc.$25K
- Bayer$7K
- Calliditas Therapeutics US Inc.$2K
- Amgen$1K
- Mallinckrodt Hospital Products Inc.$1K
- plus $4K from 17 others
Across 1 payment — averaging $3443.75 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$3K
What the payments were for
- Consulting fees$7,17510%
- Speaking & faculty fees$43,99664%
- Travel & lodging$5,8378%
- Food & beverage$11,84417%
- Education$1850%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 83 | $28,515 |
| Travere Therapeutics, Inc. | 61 | $25,201 |
| Bayer | 21 | $7,120 |
| Calliditas Therapeutics US Inc. | 8 | $2,163 |
| Amgen(2 entities) | 47 | $1,369 |
| Mallinckrodt Hospital Products Inc. | 18 | $1,106 |
| OPKO Pharmaceuticals, LLC | 61 | $934 |
| Aurinia Pharma U.S., Inc. | 7 | $413 |
| GSK | 4 | $370 |
| Vifor Pharma, Inc. | 19 | $317 |
| Novartis | 11 | $236 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 3 | $234 |
| Edwards Lifesciences | 1 | $132 |
| Daiichi Sankyo Inc. | 2 | $131 |
| Silk Road Medical, Inc. | 1 | $117 |
| Akebia Therapeutics Inc | 4 | $112 |
| Recor Medical Inc | 1 | $105 |
| Mallinckrodt Enterprises LLC | 1 | $95 |
| Nuwellis, Inc. | 4 | $92 |
| E.r. Squibb & Sons, L.L.C. | 1 | $89 |
| Fresenius USA Marketing, Inc. | 5 | $85 |
| Otsuka America Pharmaceutical, Inc. | 5 | $81 |
| Ardelyx, Inc. | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LOKELMA$26,099
- Kerendia$6,679
- TARPEYO$2,077
- Filspari$935
- ACTHAR$701
- KRYSTEXXA$457
- Rayaldee$260
- LUPKYNIS$228
- PASCAL$132
- TERLIVAZ$129
- SOLIRIS$125
- JESDUVROQ$125
- Parsabiv$117
- ENROUTE Transcarotid Neuroprotection System$117
- ENROUTE Transcarotid Stent System$117
- ENHANCE Transcarotid Peripheral Access Kit$117
- ENROUTE 0.014 Guidewire$117
- INJECTAFER$116
- FARXIGA$116
- PARADISE RENAL DENERVATION SYSTEM$105
How this compares
$69,037 in reported general payments places this provider in the 95th percentile of 388 nephrology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| KrystexxaPegloticase | 19 | $539,122 |
| FarxigaDapagliflozin Propanediol | 89 | $101,771 |
| VeltassaPatiromer Calcium Sorbitex | 22 | $37,261 |
| LokelmaSodium Zirconium Cyclosilicate | 24 | $15,878 |
| KerendiaFinerenone | 16 | $12,489 |
| Sevelamer Carbonate | 29 | $4,543 |
| Nifedipine ErNifedipine | 108 | $3,875 |
| Febuxostat | 17 | $2,817 |
| Bumetanide | 55 | $1,797 |
| Calcitriol | 125 | $1,527 |
| Torsemide | 66 | $687 |
| Hydralazine Hcl | 35 | $685 |
| Olmesartan Medoxomil | 64 | $620 |
| Olmesartan-HydrochlorothiazideOlmesartan/Hydrochlorothiazide | 14 | $618 |
| Losartan Potassium | 53 | $524 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AmgenKrystexxa | $1,369 | $539,12219 claims |
| AstraZenecaFarxiga, Lokelma | $28,515 | $117,649113 claims |
| BayerKerendia | $7,120 | $12,48916 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 388 nephrology providers in Georgia.
Other nephrology in Atlanta
- Sheldon ShoreAtlanta$474K
- Christina KleinAtlanta$137K
- Mary MuonekeAtlanta$119K
- Frederic Rahbari OskouiAtlanta$88K
- Haimanot WasseAtlanta$60K
- Janice LeaAtlanta$21K
- Vandana NiyyarAtlanta$11K
- Gautham ViswanathanAtlanta$10K
- Lara WatkinsAtlanta$8K
- Saied MurphyAtlanta$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.